Основная статистика
| LEI | 5299006YIA3L0MBW8358 |
| CIK | 1410098 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CorMedix Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 2, 2025 |
Exhibit 10.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 29, 2025, by and among CorMedix Inc., a Delaware corporation (the “Company”), Deerfield Private Design Fund IV, L.P. (“DPDF IV”), Deerfield Private Design Fund III, L.P. (“DPDF III” and, together with DPDF IV, the “Initial Holders”) and each other Holder (as defined bel |
|
| September 2, 2025 |
Exhibit 99.1 CorMedix completes ACQUIsition of MELINTA THERAPEUTICS AND ANNOUNCES NEW LEADERSHIP TEAM - Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - - Revised guidance of pro forma 2025 combined revenues, now estimated to be in |
|
| September 2, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION IS IDENTIFIED HEREIN WITH “[***].” SCHEDULES AND EXHIBITS HAVE BEEN OMITTED PURSUANT TO ITEM 601(A)(5) OF REGULATION S-K. Execution Version CONTINGENT PAYMENT AGREEMENT This CONTINGENT PAYMENT AGREEMENT (this “Agreement”), d |
|
| September 2, 2025 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 31, 2025 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Dr. Matt David (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the foregoing premis |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 CorMedix Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34473 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 2, 2025 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 Execution Version EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 28, 2025 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Susan Blum (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the fo |
|
| September 2, 2025 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 29, 2025 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Elizabeth Hurlburt (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the foregoing pr |
|
| August 12, 2025 |
Exhibit 4.1 CORMEDIX INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August 12, 2025 4.00% Convertible Senior Notes due 2030 Table of Contents Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 21 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amount 21 Secti |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 CorMedix Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 CorMedix Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34473 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 7, 2025 |
Exhibit 99.5 August 6, 2025 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, New Jersey 07922 Re: Subscription for 4.00% Convertible Senior Notes due 2030 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (the “Company”), is offering the undersigned investor (the “Investor”), on behalf of itself and each account (if any) listed on Exhibit A hereto for whom the Investor has b |
|
| August 7, 2025 |
Exhibit 2.1 CONFIDENTIAL EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of August 7, 2025, among CorMedix Inc., Coriander Bidco LLC, MELINTA THERAPEUTICS, LLC, AND Deerfield Private Design Fund IV, L.P., as the Members’ REPRESENTATIVE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFOR |
|
| August 7, 2025 |
Exhibit 4.1 CORMEDIX INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of August [12], 2025 4.00% Convertible Senior Notes due 2030 Table of Contents Page ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 21 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amount 21 Sec |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 7, 2025 |
Exhibit 99.1 CorMedix Inc. Reports second Quarter 2025 Financial Results and Provides Business Update ‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Berkeley Heights, NJ – August 7, 2025 – CorMedix Inc. (Nasdaq: CRMD) today announced fin |
|
| August 7, 2025 |
Exhibit 99.2 CorMedix TO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED SPECIALTY COMPANY WITH STRONG PRESENCE IN ACUTE CARE SETTINGS - Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - Transaction expected to be near-term accre |
|
| August 7, 2025 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF SERIES E CONVERTIBLE PREFERRED STOCK OF CORMEDIX INC. Pursuant to Section 242 of the Delaware General Corporation Law I, Joseph Todisco, Chief Executive Officer of CorMedix Inc. (the “Corporation”) a corporation organized and existing under the laws of the State of Delaware, DO HEREBY CERTIFY: A. Pursuant to its Certificate of In |
|
| August 7, 2025 |
Exhibit 99.4 Acquisition of Melinta Therapeutics August 7, 2025 Disclaimer This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27 A of the Securities Act, and Section 21 E of the Exchange, as amended (the “Exchange Act”), that are subject to risks and uncertainties . Forward - looking statements are often id |
|
| August 7, 2025 |
Selected Melinta Therapeutics, LLC Financial Information1 Exhibit 99.3 Selected Melinta Therapeutics, LLC Financial Information1 ($ in millions) 2024A Q1 2025A Q2 2025A Net Product Revenue $ 106 $ 26 $ 29 Contract Revenue 11 License and Other Revenue 2 Other Revenue2 $ 14 $ 4 $ 4 Total Revenue $ 120 $ 30 $ 33 Cost of Goods Sold $ (27 ) $ (7 ) $ (8 ) Gross Profit $ 93 $ 23 $ 26 % Margin 77 % 77 % 77 % Research & Development $ (15 ) $ (4 ) $ (5 ) Selling, |
|
| June 30, 2025 |
$85,000,000 CorMedix Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279277 Prospectus Supplement (To prospectus dated May 22, 2024) $85,000,000 CorMedix Inc. Common Stock We are offering 6,604,507 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “CRMD.” On June 25, 2025, the last reported sale price of our common stock on the Nasdaq Global Market was $14.97 per |
|
| June 30, 2025 |
Underwriting Agreement dated June 26, 2025 Exhibit 1.1 Execution Version CorMedix Inc. 6,604,507 Shares of Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York June 26, 2025 RBC Capital Markets, LLC As Representative of the several Underwriters listed on Schedule I hereto c/o RBC Capital Markets, LLC 200 Vesey Street New York, New York 10281-8098 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (th |
|
| June 30, 2025 |
CorMedix Inc. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 CorMedix Inc. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ – June 27, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its co |
|
| June 30, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 30, 2025 |
CorMedix Inc. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 CorMedix Inc. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ – June 26, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it intends to offer and sell $85.0 million of shares of its common stock in an underwritten pub |
|
| June 26, 2025 |
Subject to Completion, dated June 26, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-279277 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| June 25, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commis |
|
| June 23, 2025 |
CorMedix Inc. announces customer IMPLEMENTATION Exhibit 99.1 CorMedix Inc. announces customer IMPLEMENTATION Berkeley Heights, NJ – June 23, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 6, 2025 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – May 6, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threate |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 22, 2025 |
Letter from Marcum dated April 22, 2025 Exhibit 16.1 April 22, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by CorMedix Inc. under Item 4.01 of its Form 8-K dated April 22, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of CorMedix Inc. contained therein. Very tr |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 8, 2025 |
Exhibit 99.1 CorMedix Inc. announces preliminary FIRST quarter 2025 results and RAISES H1 2025 NET SALES GUIDANCE ‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ Berkeley Heights, NJ – April 8, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on develo |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 25, 2025 |
Insider Trading Policies and Procedures Exhibit 19.1 TITLE: INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Document No.: LEG-POL-001.1 Effective Date: October 30, 2024 Page: 1 of 12 1.0 PURPOSE 1.1 The purpose of this policy is to guide everyone who works for or provides services to CorMedix Inc. (the “Company”) concerning trading in the Company’s securities and in securities of publicly |
|
| March 25, 2025 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Berkeley Heights, NJ – March 25, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical comp |
|
| March 25, 2025 |
Exhibit 10.16 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of December 12, 2023 by and between CorMedix Inc., a Delaware corporation (the “Company”), and Beth Zelnick Kaufman (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In consideration of the foregoi |
|
| March 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 7, 2025 CORMEDIX INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 7, 2025 |
Exhibit 99.1 CorMedix Inc. announces preliminary Fourth quarter 2024 results and provides business update ‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ Berkeley Heights, NJ – January 7, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commerci |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
|
| November 14, 2024 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CorMedix Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 21900C308 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| October 30, 2024 |
Exhibit 99.1 CorMedix Inc. Reports THIRD Quarter AND NINE MONTH 2024 Financial Results and Provides Business Update ‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ Berkeley Heights, NJ – October 30, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company foc |
|
| October 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 14, 2024 |
Exhibit 99.1 CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – August 14, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announce |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| May 20, 2024 |
CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 May 20, 2024 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Division of Corporation Finance, Office of Life Sciences Re: CorMedix Inc. Registration Statement on Form S-3 Filed May 9, 2024 File No. 333-279277 Ladies and Gentlemen: Pur |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 9, 2024 |
Sales Agreement with Leerink Partners LLC dated May 9, 2024 Exhibit 1.2 CORMEDIX INC. Common Stock (par value $0.001 per share) SALES AGREEMENT May 9, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (the “Company”) and Leerink Partners LLC (the “Agent”, together with the Company, each a “Party” and collectively, the “Parties”) and hereby agree as follows: |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) CorMedix Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered and Carry Forward Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration Statement No. |
|
| May 9, 2024 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – May 9, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 12, 2024 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – March 12, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases |
|
| March 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 12, 2024 |
Separation Agreement, effective December 14, 2023, between CorMedix Inc. and Phoebe Mounts. Exhibit 10.17 Separation Agreement and Release This Separation Agreement and Release (the “Agreement”), effective December 14, 2023 (“Delivery Date”), sets forth the terms of the separation of Phoebe Mounts (“you” or “your”) from employment with CorMedix Inc. (the “Company”). If you understand and agree with these terms, please sign in the space provided below. If you and the Company sign below, t |
|
| March 12, 2024 |
Board Policy on Recouping Incentive Compensation Exhibit 97.1 Final as Approved Compensation Recoupment Policy of CorMedix Inc. Adopted to go into effect on December 1, 2023, with retroactive effectiveness to the Effective Date Article A. Purpose And General Terms Section A-1. Purpose. CorMedix Inc. (the “Company”) has adopted this Compensation Recoupment Policy (this “Policy”) to: (a) implement a mandatory clawback policy in the event of a Rest |
|
| February 14, 2024 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC Passive Investment SC 13G/A 1 sayw2402144613ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CorMedix Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 21900C308 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2024 |
CRMD / CorMedix Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: CorMedix Inc Title of Class of Securities: Common Stock CUSIP Number: 21900C308 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1 |
|
| January 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 30, 2024 |
CORMEDIX INC. announces commercial AND REiMBURSEMENT updates Exhibit 99.1 CORMEDIX INC. announces commercial AND REiMBURSEMENT updates Berkeley Heights, NJ – January 30, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced updates related to its business and anticipated launch of DefenCath®. |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 16, 2023 |
Exhibit 99.1 CORMEDIX INC. ANNOUNCES FDA APProval of Defencath® To reduce the incidence of catheter-related bloodstream infections in adult hemodialysis patients – First and only FDA-approved antimicrobial catheter lock solution in the U.S. – Company expects DefenCath to be available in Q1 2024 in the inpatient setting Berkeley Heights, NJ – November 15, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biop |
|
| November 14, 2023 |
Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – November 14, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening disea |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| October 30, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 8, 2023 |
Exhibit 99.1 CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2023 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – August 8, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| June 30, 2023 |
Form of Pre-Funded Warrant issued June 28, 2023 Exhibit 4.1 CORMEDIX INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. Number of Shares: (subject to adjustment) Original Issue Date: CorMedix Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, , or its permitted assigns (the “Holder”), is entitled to purchase fro |
|
| June 30, 2023 |
CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Exhibit 99.1 CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Berkeley Heights, NJ – June 28, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that it intends to offer and sell shares of |
|
| June 30, 2023 |
Exhibit 99.2 CORMEDIX INC. ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Berkeley Heights, NJ – June 28, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the pricing of its previously |
|
| June 30, 2023 |
Underwriting Agreement dated June 28, 2023 Exhibit 1.1 CorMedix Inc. 7,500,000 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,500,625 Shares of Common Stock ($0.001 par value per share) Underwriting Agreement New York, New York June 28, 2023 RBC Capital Markets, LLC Truist Securities, Inc. As Representatives of the several Underwriters listed on Schedule I hereto c/o RBC Capital Markets, LLC 200 Vesey Street New York, New Y |
|
| June 30, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258756 Prospectus Supplement (To prospectus dated August 20, 2021) CorMedix Inc. 7,500,000 Shares of Common Stock and Pre-Funded Warrants to Purchase Up to 2,500,625 Shares of Common Stock 2,500,625 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 7,500,000 shares of our common stock and, in lieu of common stock to cert |
|
| June 28, 2023 |
Subject to Completion, dated June 28, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-258756 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| June 21, 2023 |
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH Exhibit 99.1 CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ – June 21, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the resubmission of the New Drug Ap |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 16, 2023 |
CorMedix Inc. ANNOUNCES RESUBMISSION Of New drug application for defencath Exhibit 99.1 CorMedix Inc. ANNOUNCES RESUBMISSION Of New drug application for defencath Berkeley Heights, NJ – May 16, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the New Drug Application for DefenCath was resubmitted |
|
| May 15, 2023 |
Exhibit 10.1 CORMEDIX INC. INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [●], between CorMedix Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”). WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other capacities unless they are provided with adequate protec |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| May 15, 2023 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – May 15, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, |
|
| April 26, 2023 |
CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES Berkeley Heights, NJ – April 26, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that following its Type A meeting with the FDA, the Comp |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 17, 2023 |
CORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS Exhibit 99.1 CORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS Berkeley Heights, NJ – April 17, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMe |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commi |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 30, 2023 |
Exhbit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – March 30, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 30, 2023 |
Exhibit 10.1 * Information in this exhibit marked [***] has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated as private or confidential. LICENSE AND ASSIGNMENT AGREEMENT between ND PARTNERS LLC and CORMEDIX, INC. LICENSE AND ASSIGNMENT AGREEMENT This License and Assignment Agreement (hereinafter referred to as this “Agreement”), ef |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 3, 2023 |
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Berkeley Heights, NJ – March 2, 2023 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced updates related to the FDA compliance remediation activities at its prim |
|
| February 14, 2023 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC - SC 13G/A Passive Investment SC 13G/A 1 brhc10047775sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CorMedix Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 21900C308 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| November 10, 2022 |
Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ – November 10, 2022 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and disea |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| October 26, 2022 |
Amended and Restated 2019 Omnibus Stock Incentive Plan Exhibit 99.1 Amended and Restated CORMEDIX INC. 2019 omnibus stock INCENTIVE PLAN Approved by the Board August 23, 2022 and by the Stockholders on October 13, 2022 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel; to provide additional incentives to Employees, Directors and Consultants to contribute to the successful performance of the Compa |
|
| October 26, 2022 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CorMedix Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock(1) 457(c) and 457(h |
|
| October 26, 2022 |
As filed with the Securities and Exchange Commission on October 26, 2022 As filed with the Securities and Exchange Commission on October 26, 2022 Registration Statement No. |
|
| October 21, 2022 |
Letter from Friedman LLP to the Securities and Exchange Commission dated October 21, 2022. Exhibit 16.1 October 21, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: CorMedix Inc. Commission File Number 001-34673 Commissioners: We have read the statements made by CorMedix Inc. under Item 4.01 of its Form 8-K dated October 21, 2022. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| August 11, 2022 |
Exhibit 99.1 CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ ? August 11, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammat |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 9, 2022 |
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Berkeley Heights, NJ ? August 8, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates related to the FDA review of the DefenCath New Drug Application (NDA |
|
| August 9, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| May 12, 2022 |
CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES Exhibit 99.2 CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES Berkeley Heights, NJ ? May 12, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its leadership team and changes regarding its internat |
|
| May 12, 2022 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? May 12, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| March 29, 2022 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? March 29, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammato |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 28, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 28, 2022 |
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Exhibit 99.1 CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ ? March 28, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the resubmission of the New Drug Applic |
|
| March 21, 2022 |
Exhibit 99.1 CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry Berkeley Heights, NJ ? March 17, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commerc |
|
| March 21, 2022 |
Executive Employment Agreement, dated March 16, 2022, between CorMedix Inc. and Joseph Todisco. Exhibit 10.1 CORMEDIX INC. EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of March 16, 2022 (the ?Effective Date?), by and between CorMedix Inc., a Delaware corporation (the ?Company?), and Joseph Todisco (?Executive?). Each of the Company and Executive is referred to herein as a ?Party? and together they are referred to as the ?Parties.? TERMS In |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2022 CORMEDIX INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| February 28, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 28, 2022 |
CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Exhibit 99.1 CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ ? February 28, 2022 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted the New Drug Application (NDA) for |
|
| February 28, 2022 |
Exhibit 99.2 CORMEDIX DefenCath TM : A potentially new standard - of - care in the prevention of catheter related blood stream infections CORMEDIX This presentation contains certain statements that constitute forward - looking statements within the meaning of the federal securities laws . Statements that are not historical facts, including statements about our beliefs and expectations, are forward |
|
| February 14, 2022 |
CRMD / CorMedix Inc. / NOMURA HOLDINGS INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CorMedix Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 21900C308 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| December 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 CORMEDIX INC. |
|
| December 23, 2021 |
Exhibit 10.2 [CorMedix Letterhead] Personal and Confidential [DATE] [Employee Name] Subject: CorMedix Inc. Special Performance Bonus Dear [First Name]: On behalf of CorMedix Inc. (the ?Company?), I am pleased to inform you that you will be eligible to receive a special cash performance bonus (?Bonus?) under the CorMedix Inc. Executive Bonus Plan (?Plan?). The Bonus will be payable based on the ach |
|
| December 23, 2021 |
Exhibit 10.1 CORMEDIX INC. EXECUTIVE BONUS PLAN I. Purpose. The purpose of the CorMedix Inc. Executive Bonus Plan (the ?Plan?) is to provide a means whereby CorMedix Inc. (the ?Company?) may provide incentive compensation to its eligible employees to serve as an incentive for employee performance and retention. The Plan is effective as of December 20, 2021. II. Definitions. Whenever used in this P |
|
| December 13, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| November 9, 2021 |
Exhibit 10.2 Separation Agreement and Release This Separation Agreement and Release (the ?Agreement?) sets forth the terms of the separation of John L. Armstrong, Jr. (?you? or ?your?) from employment with CorMedix Inc. (the ?Company?). If you understand and agree with these terms, please sign in the space provided below. If you and the Company sign below, this will be a legally binding document r |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| November 9, 2021 |
Exhibit 10.1 Separation Agreement and Release This Separation Agreement and Release (the ?Agreement?) sets forth the terms of your separation from employment with CorMedix Inc. (the ?Company?). If you understand and agree with these terms, please sign in the space provided below. If you and the Company sign below, this will be a legally binding document representing the entire agreement between yo |
|
| November 9, 2021 |
Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? November 9, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, t |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. |
|
| October 29, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| October 29, 2021 |
Exhibit 10.1 October 26, 2021 Matthew David, M.D. Re: Interim Chief Executive Officer Letter Agreement Dear Matt: As we have discussed, you will serve as the interim Chief Executive Officer of Cormedix Inc. (?Interim CEO?), effective as of October 4, 2021, until such time as Cormedix appoints a new Chief Executive Officer. You understand and agree that you will also continue to serve as CorMedix?s |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| September 7, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| September 7, 2021 |
CORMEDIX INC. ANNOUNCES REGULATORY UPDATE Exhibit 99.1 CORMEDIX INC. ANNOUNCES REGULATORY UPDATE Berkeley Heights, NJ ? September 7, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update with respect to its resubmission timeline for the DefenCath New Drug Application (? |
|
| August 18, 2021 |
CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 August 18, 2021 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada D. Sarmento, Attorney-Advisor Re: CorMedix Inc. Registration Statement on Form S-3 Filed August 12, 2021 File No. 333-258756 Ladies and Gentlemen: Pursuant to Rule 46 |
|
| August 12, 2021 |
Exhibit 10.1 IN ACCORDANCE WITH ITEM 601(b)(10) of REGULATION S-K, CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT 10.10 BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH INFORMATION IS IDENTIFIED BY [***] EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of April 29, 2021 by an |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 12, 2021 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To prospectus dated November 25, 2020) Registration No. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 12, 2021 |
As filed with the Securities and Exchange Commission on August 12, 2021 As filed with the Securities and Exchange Commission on August 12, 2021 Registration Statement No. |
|
| August 12, 2021 |
Exhibit 1.1 CORMEDIX INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement August 12, 2021 Truist Securities, Inc. 3333 Peachtree Road NE, 11th Floor Atlanta, Georgia 30326 JMP Securities LLC 600 Montgomery Street, Suite 1100 San Francisco, California 94111 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (the ?Company?), Truist Securities, Inc. (?Truist?) an |
|
| August 12, 2021 |
Exhibit 99.1 CORMEDIX INC. REPORTS Second QUARTER and six month 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? August 12, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammat |
|
| August 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Comm |
|
| May 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 14, 2021 |
Exhibit 99.1 CorMedix Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ ? May 13, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today |
|
| May 14, 2021 |
Exhibit 99.1 CorMedix Inc. Announces Appointment of Chief Commercial Officer Thomas Nusbickel to join CorMedix as Chief Commercial Officer; Brings significant experience in renal product launches and commercialization Berkeley Heights, NJ ? May 13, 2021 ? CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| April 15, 2021 |
CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA Exhibit 99.1 CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA Berkeley Heights, NJ — April 14, 2021 — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has met with the US Food and Drug Administration (FDA) to d |
|
| April 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 30, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 30, 2021 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – March 30, 2021 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammato |
|
| March 30, 2021 |
Exhibit 10.10 IN ACCORDANCE WITH ITEM 601(b)(10) of REGULATION S-K, CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT 10.10 BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of May 11, 2020 by and between CorMedix Inc., a Delaware corpo |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 12, 2021 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of March 10, 2021 (the ?Effective Date?) by and between CorMedix Inc., a Delaware corporation (the ?Company?), and Elizabeth Masson-Hurlburt (?Executive?). Each of the Company and Executive is referred to herein as a ?Party? and together they are referred to as the ?Parties.? TERMS In cons |
|
| March 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 1, 2021 |
CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION Exhibit 99.1 CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION Berkeley Heights, NJ — March 1, 2021 — CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration (FDA) c |
|
| February 11, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) CorMedix Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21900C308 (CUSIP Number) Elliott Investment Management, L.P. Phillips Point, East Tower 777 South Flagler Drive, Suite 1000 West Palm Beach, FL 33401 with a copy to |
|
| February 5, 2021 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (to Prospectus dated November 25, 2020) Registration No. |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 20-5894890 (State of other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 300 Conn |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-34673 CORMEDIX INC. NYSE American LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 300 Connell Drive, Sui |
|
| January 21, 2021 |
CORMEDIX INC. To begin trading on the Nasdaq Stock exchange Exhibit 99.1 CORMEDIX INC. To begin trading on the Nasdaq Stock exchange Berkeley Heights, NJ – January 21, 2021 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved for listing on the Nasdaq Global Market. T |
|
| January 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| December 18, 2020 |
Submission of Matters to a Vote of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
|
| November 27, 2020 |
Exhibit 1.1 CORMEDIX INC. Common Stock (par value $0.001 per share) Amended and Restated At Market Issuance Sales Agreement November 27, 2020 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Needham & Company, LLC 250 Park Avenue New York, NY 10177 Ladies and Gentlemen: CorMedix Inc., a Delaware corporation (the “Company”) and B. Riley Securities, Inc. (formerly B. Riley FB |
|
| November 27, 2020 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 27, 2020 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (To prospectus dated November 25, 2020) Registration No. |
|
| November 23, 2020 |
CorMedix Inc. 300 Connell Drive, Suite 4200 Berkeley Heights, NJ 07922 November 23, 2020 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Life Sciences Re: CorMedix Inc. Registration Statement on Form S-3 Filed November 5, 2020 File No. 333-249901 Ladies and Gentlemen: Pursuant to Rule 461 under |
|
| November 18, 2020 |
Exhibit 99.1 CORMEDIX INC. Announces fda DECISION THAT ADVISORY COMMITTEE MEETING FOR new drug application for defencath IS NOT NEEDED ● PDUFA date remains February 28, 2021 ● Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients Berkeley Heights, NJ – November 18, 2020 – CorMedix Inc. (NYSE American: CRM |
|
| November 18, 2020 |
Other Events, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
|
| November 5, 2020 |
Exhibit 99.1 CORMEDIX INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – November 5, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory dis |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| November 5, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| November 5, 2020 |
As filed with the Securities and Exchange Commission on November 5, 2020 Registration Statement No. |
|
| November 4, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| November 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| November 2, 2020 |
Exhibit 99.1 CorMedix Appoints Greg Duncan to its Board of Directors Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Berkeley Heights, NJ – November 2, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infecti |
|
| October 14, 2020 |
Second Amended and Restated Bylaws as amended October 8, 2020 Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF CORMEDIX INC. AS AMENDED OCTOBER 8, 2020 ARTICLE I STOCKHOLDERS Section 1.1 Annual Meetings. An annual meeting of stockholders to elect directors and transact such other business as may properly be presented to the meeting shall be held at such time and at such place, within or without the State of Delaware, as may be designated by the Board of Di |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Comm |
|
| September 17, 2020 |
Exhibit 99.1 Cormedix Appoints Paulo Costa to its Board of Directors Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Berkeley Heights, NJ – September 17, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infec |
|
| September 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (C |
|
| August 31, 2020 |
Exhibit 99.1 CORMEDIX INC. Announces fda acceptance for filing and priority review of new drug application for defencath · FDA sets PDUFA goal date of February 28, 2021 · Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients Berkeley Heights, NJ – August 31, 2020 – CorMedix Inc. (NYSE American: CRMD), a b |
|
| August 31, 2020 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Comm |
|
| August 31, 2020 |
Prospectus Supplement Filed pursuant to Rule 424(b)(5) (to Prospectus dated April 16, 2018) Registration No. |
|
| August 10, 2020 |
Exhibit 99.1 CORMEDIX INC. REPORTS Second QUARTER and six month 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – August 10, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and in |
|
| August 10, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| August 10, 2020 |
CRMD / CorMedix Inc. / Elliott Investment Management L.P. - CORMEDIX INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CorMedix Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21900C308 (CUSIP Number) Elliott Investment Management, L.P. 40 West 57th Street New York, NY 10019 with a copy to: Eleazer Klein, Esq. Marc Weingarten, Esq. Schulte Roth & Zabel LLP 9 |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Comm |
|
| July 29, 2020 |
CorMedix Announces Pricing of $20M Public Offering of Common Stock EX-99.1 4 ea124677ex99-1cormedixinc.htm PRESS RELEASE DATED JULY 28, 2020 Exhibit 99.1 CorMedix Announces Pricing of $20M Public Offering of Common Stock Berkeley Heights, NJ – July 28, 2020 – CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory |
|
| July 29, 2020 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commis |
|
| July 29, 2020 |
Exhibit 1.1 Execution Version 4,444,444 Shares CorMedix Inc. Common Stock ($0.001 par value) UNDERWRITING AGREEMENT July 28, 2020 SUNTRUST ROBINSON HUMPHREY, INC. JMP Securities LLC As Representatives of the Several Underwriters c/o SunTrust Robinson Humphrey, Inc. 3333 Peachtree Road, 10th Floor Atlanta, Georgia 30326 c/o JMP Securities LLC 600 Montgomery Street, Suite 1100 San Francisco, Califor |
|
| July 29, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-223562 Prospectus Supplement (To prospectus dated April 16, 2018) 4,444,444 shares Common Stock We are offering 4,444,444 shares of our common stock, $0.001 par value per share. Our common stock is listed on the NYSE American under the symbol “CRMD.” On July 27, 2020, the last reported sale price of our common stock on the NYSE American was $6. |
|
| July 27, 2020 |
Subject to Completion, Dated July 27, 2020. 424B5 1 ea124335-424b5cormedix.htm PROSPECTUS SUPPLEMENT The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities |
|
| July 8, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commiss |
|
| July 8, 2020 |
CORMEDIX INC. REPORTS SUbmission of defencath™ new drug application Priority Review of NDA Requested Exhibit 99.1 CORMEDIX INC. REPORTS SUbmission of defencath™ new drug application Priority Review of NDA Requested Berkeley Heights, NJ – July 8, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that all of the modules for the |
|
| May 11, 2020 |
CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER Exhibit 99.1 CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER Berkeley Heights, NJ — May 11, 2020 — CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has appointed Matt David, M.D. as the Company’s Executive Vic |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commiss |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 CORMEDIX INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 11, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX INC. |
|
| May 11, 2020 |
Exhibit 99.1 CORMEDIX INC. REPORTS First QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – May 11, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2020 CORMEDIX INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 23, 2020 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of April 17, 2020 (the “Effective Date”) by and between CorMedix Inc., a Delaware corporation (the “Company”), and John L. Armstrong, Jr. (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS In conside |
|
| April 22, 2020 |
Exhibit 99.1 CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program Berkeley Heights, NJ – April 22, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announce |
|
| April 22, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commi |
|
| April 8, 2020 |
Exhibit 99.1 April 7, 2020 Dear Shareholder, The COVID-19 global epidemic is causing an unprecedented impact on the global biopharmaceutical community. In light of the important objectives ahead of us, we felt it was important to provide an update to our shareholders on the impact of the pandemic on CorMedix’s operations and objectives. Most importantly, we are committed to the health and safety o |
|
| April 8, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commis |
|
| March 16, 2020 |
Description of Capital Stock of CorMedix Inc. Exhibit 4.5 DESCRIPTION OF CAPITAL STOCK OF CORMEDIX INC. Common Stock The following is a summary of certain provisions of the capital stock of CorMedix Inc. (referred to herein as “we,” “us,” “our” and “Company”). Such summary does not purport to be complete. You should refer to our Amended and Restated Certificate of Incorporation, as amended, and our Amended and Restated Bylaws and each Certifi |
|
| March 16, 2020 |
Exhibit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company in process of submitting New Drug Application (NDA) for Neutrolin® for prevention of catheter-related blood stream infections via a rolling review granted by FDA Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ – March 16, 2020 – CorMedix Inc |
|
| March 16, 2020 |
CRMD / CorMedix Inc. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34673 CORMEDIX INC. |
|
| March 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Commi |
|
| February 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| February 4, 2020 |
Exhibit 99.1 CORMEDIX APPROVed TO SELL $5.5 Million OF NOL Tax Benefits Through The New Jersey Economic Development Authority PROGRAM Berkeley Heights, NJ – February 3, 2020 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it |
|
| February 4, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| February 3, 2020 |
CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application Exhibit 99.1 CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application Berkeley Heights, NJ — February 3, 2020 — CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration |
|
| February 3, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 f8k020320cormedixinc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2020 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other juris |
|
| December 17, 2019 |
CRMD / CorMedix Inc. S-8 - - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 17, 2019 Registration Statement No. |
|
| November 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2019 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Co |
|
| November 27, 2019 |
2019 Omnibus Stock Incentive Plan Exhibit 10.1 CORMEDIX INC. 2019 omnibus stock INCENTIVE PLAN Approved by the Board October 16, 2019 and by the Stockholders on November 26, 2019 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel; to provide additional incentives to Employees, Directors and Consultants to contribute to the successful performance of the Company and any Related |
|
| November 14, 2019 |
CRMD / CorMedix Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34673 CORMEDIX |
|
| November 6, 2019 |
CorMedix Inc. Announces a Change to its Senior Leadership Exhibit 99.1 PRESS RELEASE CorMedix Inc. Announces a Change to its Senior Leadership Berkeley Heights, NJ — November 6, 2019 — CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the Company and Robert Cook, the Chief Financial Of |
|
| November 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 CORMEDIX INC. (Exact name of registrant as specified in its charter) Delaware 001-34673 20-5894890 (State of other jurisdiction of incorporation or organization) (Com |
|
| October 17, 2019 |
CRMD / CorMedix Inc. DEF 14A - - DEFINITIVE PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240. |
|
| October 17, 2019 |
CRMD / CorMedix Inc. DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement. |
|
| October 16, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 16, 2019 CORMEDIX INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| October 16, 2019 |
CORMEDIX COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA Pre-NDA Meeting Scheduled Exhibit 99.1 CORMEDIX COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA Pre-NDA Meeting Scheduled Berkeley Heights, NJ – October 16, 2019 – CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed its interaction with |
|
| October 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2019 CORMEDIX INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| October 1, 2019 |
Exhibit 10.1 EXECUTION COPY EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ” Agreement”) is made as of September 26, 2019 (the “Effective Date”) by and between CorMedix Inc., a Delaware corporation (the “Company”), and Khoso Baluch (“Executive”). Each of the Company and Executive is referred to herein as a “Party” and together they are referred to as the “Parties.” TERMS |
